MBX 2109
Phase 2Completed 0 watching 0 views this week⚡ Active
47
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hypoparathyroidism
Conditions
Hypoparathyroidism
Trial Timeline
Aug 8, 2024 → Jun 4, 2025
NCT ID
NCT06465108About MBX 2109
MBX 2109 is a phase 2 stage product being developed by MBX Biosciences for Hypoparathyroidism. The current trial status is completed. This product is registered under clinical trial identifier NCT06465108. Target conditions include Hypoparathyroidism.
Hype Score Breakdown
Clinical
17
Activity
12
Company
5
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06465108 | Phase 2 | Completed |
Competing Products
9 competing products in Hypoparathyroidism
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| 400 µg of MBX 2109 once-weekly by subcutaneous injection + 200-1600 µg of MBX 2109 once-weekly by subcutaneous injection | MBX Biosciences | Phase 2 | 47 |
| PCO371 + Placebo | Chugai Pharmaceutical | Phase 1 | 33 |
| recombinant human somatotropin | Eli Lilly | Pre-clinical | 23 |
| Palopegteriparatide | Ascendis Pharma | Pre-clinical | 20 |
| Palopegteriparatide (TransCon PTH) | Ascendis Pharma | Pre-clinical | 20 |
| Palopegteriparatide | Ascendis Pharma | Pre-clinical | 20 |
| EnteraBio's Oral Parathyroid Hormone (1-34) | Entera Bio | Phase 2 | 44 |
| EBP05 + Forteo 0.02 mg + EBP11 + EBP22 + EBP11-F2 + EBP11-F4 + EBP11-F1 + EBP11-F5 | Entera Bio | Phase 1 | 25 |
| EB612 (EBP05) + NATPARA/NATPAR | Entera Bio | Phase 2 | 44 |
Other Products from MBX Biosciences
400 µg of MBX 2109 once-weekly by subcutaneous injection + 200-1600 µg of MBX 2109 once-weekly by subcutaneous injectionPhase 2
47
MBX 1416 (INN imapextide)Phase 2
47
MBX 4291 + PlaceboPhase 1
28
MBX 1416 (Part A) + MBX 1416 (Part B) + Placebo + MBX 1416 (Part C)Phase 1
28
MBX 2109 (Part A) + MBX 2109 (Part B) + PlaceboPhase 1
28